z-logo
open-access-imgOpen Access
Dendritic Cells Trigger Tumor Cell Death by a Nitric Oxide-Dependent Mechanism
Author(s) -
Alexandra Nicolas,
Dominique Cathelin,
Nicolas Larmonier,
Jennifer Fraszczak,
Pierre-Emmanuel Puig,
André Bouchot,
Andrew Bateman,
Éric Solary,
Bernard Bonnotte
Publication year - 2007
Publication title -
the journal of immunology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 2.737
H-Index - 372
eISSN - 1550-6606
pISSN - 0022-1767
DOI - 10.4049/jimmunol.179.2.812
Subject(s) - perforin , dendritic cell , granzyme , microbiology and biotechnology , granzyme b , cytotoxic t cell , biology , apoptosis , programmed cell death , immune system , follicular dendritic cells , bone marrow , cancer research , immunology , t cell , antigen presenting cell , cd8 , in vitro , biochemistry
Dendritic cells (DCs) are well known for their capacity to induce adaptive antitumor immune response through Ag presentation and tumor-specific T cell activation. Recent findings reveal that besides this role, DCs may display additional antitumor effects. In this study, we provide evidence that LPS- or IFN-gamma-activated rat bone marrow-derived dendritic cells (BMDCs) display killing properties against tumor cells. These cytotoxic BMDCs exhibit a mature DC phenotype, produce high amounts of IL-12, IL-6, and TNF-alpha, and retain their phagocytic properties. BMDC-mediated tumor cell killing requires cell-cell contact and depends on NO production, but not on perforin/granzyme or on death receptors. Furthermore, dead tumor cells do not exhibit characteristics of apoptosis. Thus, intratumoral LPS injections induce an increase of inducible NO synthase expression in tumor-infiltrating DCs associated with a significant arrest of tumor growth. Altogether, these results suggest that LPS-activated BMDCs represent powerful tumoricidal cells which enforce their potential as anticancer cellular vaccines.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom